Comparison
Selank vs Semaglutide
Side-by-side of Selank and Semaglutide. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Selank
Selank peptide benefits: tuftsin analog heptapeptide, intranasal anxiolytic and nootropic. Russian clinical data, dosing, half-life, safety.
Semaglutide
Semaglutide for weight loss: GLP-1 agonist (Ozempic, Wegovy) drives 15-17% mean loss at 2.4 mg/week in STEP trials. Watch lean-mass loss.
Effects at a glance
Selank
- •Synthetic heptapeptide analog of tuftsin developed in Russia in the 1990s
- •Approved in Russia for generalized anxiety disorder and asthenic conditions
- •Russian RCTs report anxiolytic effects comparable to medazepam without sedation or dependence
- •Modulates GABAergic and serotonergic signaling and BDNF expression in preclinical models
- •Most commonly administered intranasally; subcutaneous use is anecdotal
- •No Western-validated trials; not FDA approved; research-use-only outside Russia
Semaglutide
- •Long-acting GLP-1 receptor agonist with a ~7-day half-life that supports once-weekly subcutaneous dosing
- •STEP trials reported ~15 to 17% mean body-weight loss at 2.4 mg/week over 68 weeks in adults with obesity
- •Lowers HbA1c by ~1.0 to 1.8 percentage points in type 2 diabetes versus placebo
- •SELECT trial showed reduced major cardiovascular events in adults with prior CVD and overweight or obesity
- •Up to 25 to 40% of weight lost can be lean mass; pairing with resistance training and protein intake mitigates this
- •GI effects (nausea, vomiting, constipation) drive most discontinuations and ease with slow titration
Side-by-side
| Attribute | Selank | Semaglutide |
|---|---|---|
| Category | peptide | pharmaceutical |
| Also known as | TP-7, Tuftsin analog | Ozempic, Wegovy, Rybelsus |
| Half-life (hr) ↗ | 0.5 | 168 |
| Typical dose (mg) ↗ | 0.4 | 2.4 |
| Dosing frequency | 2-3x daily (intranasal) | weekly (SC); daily (oral Rybelsus) |
| Routes | intranasal, subcutaneous | subcutaneous, oral |
| Onset (hr) | 0.25 | 24 |
| Peak (hr) | 1 | 72 |
| Molecular weight | 751.85 | 4113.58 |
| Molecular formula | C33H57N11O9 | - |
| Mechanism | Modulates GABAergic, serotonergic, and dopaminergic signaling. Increases BDNF expression in hippocampal neurons in preclinical models. Modulates enkephalin levels and immune cytokine signaling via tuftsin-like activity. | Long-acting GLP-1 receptor agonist; potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic satiety centers. |
| Legal status | Approved as a prescription anxiolytic in Russia; not FDA approved; research-use-only grey market in most other jurisdictions | Prescription only (FDA-approved, EMA-approved) |
| WADA status | unknown | allowed |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status outside Russia | Rx only (not a controlled substance); FDA-approved for type 2 diabetes (2017) and chronic weight management (2021) |
| Pregnancy | Not recommended; insufficient data | Not recommended; discontinue 2 months before planned pregnancy |
| CAS | 129954-34-3 | 910463-68-2 |
| PubChem CID | 11765600 | 56843331 |
| Wikidata | Q4416793 | Q27089394 |
Safety profile
Selank
Common side effects
- mild nasal irritation (intranasal)
- transient drowsiness (uncommon)
- mild headache
Contraindications
- pregnancy
- lactation
- severe psychiatric disorder (insufficient data)
Interactions
- benzodiazepines: additive anxiolytic effect; potential for over-sedation when stacked(moderate)
- SSRIs: no documented adverse interaction; co-administration described in Russian protocols(minor)
Semaglutide
Common side effects
- nausea
- vomiting
- diarrhea
- constipation
- decreased appetite
- injection-site reactions
- fatigue
Contraindications
- personal or family history of medullary thyroid carcinoma
- multiple endocrine neoplasia type 2
- pregnancy
- history of pancreatitis (use caution)
Interactions
- insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
- sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
- oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
- warfarin: monitor INR due to altered absorption(moderate)
Which Should You Take?
Semaglutide comes out ahead for most readers on the criteria we weight: 2 catalogued goals, prescription-only, oral dosing, with a Tier-A outcome catalogued. Selank is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Selank.
- → If your priority is anxiety reduction, pick Selank.
- → If your priority is metabolic health and glucose control, pick Semaglutide.
- → If your priority is fat loss, pick Semaglutide.
Edge case: If you cannot self-administer injections, Semaglutide is the only oral option in this pair.
Default choice: Semaglutide. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Selank only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Selank and Semaglutide?
Selank and Semaglutide differ in category (peptide vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Selank or Semaglutide?
Selank half-life is 0.5 hours; Semaglutide half-life is 168 hours.
Can you stack Selank with Semaglutide?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper